These results suggest that ERBB2 gene silencing by epigenetic regulation during EMT is an authentic mechanism of downregulated HER2 in the mesenchymal-like cells and the main mechanism of resistance of HER2-positive breast cancer cells to trastuzumab and lapatinib. The gene discussed is ERBB2; the disease is breast carcinoma.